Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02453841 · ClinicalTrials.gov registry record · NA
Prospective Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption
A NA study of Adenoidectomy and Functional Endoscopic Sinus Surgery (FESS), sponsored by Richard Cartabuke.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT02453841: Completed NA study of Adenoidectomy and Functional Endoscopic Sinus Surgery (FESS), sponsored by Richard Cartabuke.
NCT02453841 is a NA study of Adenoidectomy and Functional Endoscopic Sinus Surgery (FESS) that has completed, run by Richard Cartabuke. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02453841, a NA study of Adenoidectomy and Functional Endoscopic Sinus Surgery (FESS), has completed, sponsored by Richard Cartabuke.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
This proposed study will assess the hemodynamic effects and measure the systemic absorption of topically applied oxymetazoline in patients undergoing functional endoscopic sinus surgery, turbinate surgery, or adenoidectomy. These patients will be receiving oxymetazoline as standard of care during the surgery.
Primary Outcome
Blood pressure was recorded at 5 minute intervals until discharge from the post-anesthesia care unit (PACU) or the final blood draw (150 mins. after administration), whichever came first.
Conditions Studied
Interventions
- DRUG Oxymetazoline
Study Locations (1)
Ohio
- Nationwide Children's Hospital - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-12 |
| Est. Completion | 2017-04-20 |
| Phase | NA |
What the finished NCT02453841 record still lists
NCT02453841 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Adenoidectomy appearing as the primary indexed condition, and to 1 intervention - of which Oxymetazoline is the first listed.
NCT02453841 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT02453841 about?
NCT02453841 is a clinical study titled "Prospective Hemodynamic and Pharmacokinetic Analysis of Oxymetazoline Absorption". This proposed study will assess the hemodynamic effects and measure the systemic absorption of topically applied oxymetazoline in patients undergoing functional endoscopic sinus surgery, turbinate surgery, or adenoidectomy. These patients will be receiving oxymetazoline as standard of care during th...
What is the current status of trial NCT02453841?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2015-12. Estimated completion is 2017-04-20.
What conditions does trial NCT02453841 study?
This clinical trial studies the following conditions: Adenoidectomy, Functional Endoscopic Sinus Surgery (FESS), Turbinate Surgery.
What interventions are being tested in trial NCT02453841?
The interventions under investigation include: Oxymetazoline (DRUG).
Who is sponsoring clinical trial NCT02453841?
This trial is sponsored by Richard Cartabuke, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02453841 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Adenoidectomy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02453841's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia